FDA approved Priovant's Lisraya (brepocitinib) as the first targeted therapy for dermatomyositis, Gilead's Bixlenvo as the ...
President Donald Trump’s administration is preparing to announce a new round of drug-pricing agreements with midsize biotech ...
Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs ...
ACTO CEO Parth Khanna on why sales reps still matter — and how human intelligence plus empathetic agents is the winning formula for field teams.
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical ...
Eli Lilly and Company announced results from a real-world study of adults over 55 with obesity or overweight showing that ...
FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major ...
Pharmaceutical Executive spoke with K2 Therapeutics’ CEO Dr. Ying Huang about the growing shift towards globally sourced innovation and the increased focus on foreign partnerships. The push has become ...
DualityBio has licensed its Dupac next-generation ADC payload platform to Genentech, and Teva has entered a stalking horse bid to acquire BioXcel's Igalmi. Dealmaking activity spanned oncology and ...
FDA approves Imaavy as the first treatment for warm autoimmune hemolytic anemia, McKesson agrees to acquire Precision ...
The FDA has approved daraxonrasib (brand name Rasonque) for adults with metastatic pancreatic adenocarcinoma who have ...
A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results